Top 12 Stock Recommendations. In this article, we will take a look at where AbbVie Inc. (NYSE:ABBV) stands against other top ...

AbbVie is a popular stock with dividend investors for its high starting yield and continuous dividend increases. AbbVie is a Dividend King with over 50 consecutive annual dividend raises. The streak ...

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA ...

AbbVie (NYSE:ABBV), a biopharmaceutical company, is engaged in the research and development, manufacture, commercialization, ...

The latest price target for AbbVie (NYSE:ABBV) was reported by Guggenheim on April 29, 2025. The analyst firm set a price target for $216.00 expecting ABBV to rise to within 12 months (a possible ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AbbVie generated $56 billion in revenue, achieving an operating profit of $12 billion and a net income of $4.3 billion, ...

Johnson & Johnson JNJ and AbbVie ABBV are two major U.S. pharmaceutical companies with robust pipelines and global operations ...

BofA lowered the firm’s price target on AbbVie (ABBV) to $200 from $223 and keeps a Neutral rating on the shares. The firm updated estimates for 2025 and beyond ahead of Q1 results due on Friday ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. AbbVie is expected to post earnings of $3.11 ...